Targeted SLNs for management of HIV-1 associated dementia

References

• Wiley CA, Schrier RD, Nelson JA, et al. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986;83:7089–93
   PubMed Web of Science ®Google Scholar
• Buescher JL, Gross S, Gendelman HE, Ikezu T. The neuropathogenesis of HIV-1 infection. Handb Clin Neurol 2007;85:45–67
   PubMedGoogle Scholar
• Perez-Matute P, Perez-Martinez L, Blanco JR, Oteo JA. Role of mitochondria in HIV infection and associated metabolic disorders: focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev 2013;2013: Article ID 493413, doi:10.1155/2013/493413
   PubMed Web of Science ®Google Scholar
• Agrawal L, Maxwell CR, Peters PJ, et al. Complexity in human immunodeficiency virus type 1 (HIV-1) co-receptor usage: roles of CCR3 and CCR5 in HIV-1 infection of monocyte-derived macrophages and brain microglia. J Gen Virol 2009;90:710–22
   PubMed Web of Science ®Google Scholar
• Patel CA, Mukhtar M, Pomerantz RJ. Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol 2000;74:9717–26
   PubMed Web of Science ®Google Scholar
• Parakh S, Spencer DM, Halloran MA, et al. Redox regulation in amyotrophic lateral sclerosis. Oxid Med Cell Longev 2013;2013: Article ID 408681, doi:10.1155/2013/408681
   PubMed Web of Science ®Google Scholar
• Mattson MP, Haughey NJ, Nath A. Cell death in HIV dementia. Cell Death Differ 2005;12:893–904
   PubMed Web of Science ®Google Scholar
• Conant K, Venkatesan A, Nath A. Methamphetamine and HIV infection, role in neurocognitive dysfunction. Anti-Inflammatory Anti-Allergy Agents Med Chem 2009;8:184–91
   Google Scholar
• WIPO. Patent No. WO/1990011761/19901018
   Google Scholar
• Liu J, Xu P, Collins C, et al. HIV-1 Tat protein increases microglial outward K(+) current and resultant neurotoxic activity. PLoS One 2013;8:e64904
   PubMed Web of Science ®Google Scholar
• Dreyer EB, Kaiser PK, Offermann JT, Lipton SA. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990;248:364–7
   PubMed Web of Science ®Google Scholar
• Vangani S, Li X, Zhou P, et al. Dissolution of poorly water-soluble drugs in biphasic media using USP 4 and fiber optic system. Clin Res Reg Affairs 2009;26:8–19
   Google Scholar
• Muller RH, Karsten M, Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77
   PubMed Web of Science ®Google Scholar
• Muller RH, Maaben S, Weyhers H, Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J Drug Target 1996;4:161–70
   PubMed Web of Science ®Google Scholar
• Lim SB, Banerjee A, Onyuksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Contr Rel 2012;163:34–45
   PubMed Web of Science ®Google Scholar
• Souto EB, Wissing SA, Barbosa CM, Muller RH. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004;278:71–7
   PubMed Web of Science ®Google Scholar
• Jain A, Jain SK. Brain targeting using surface functionalized nanocarriers. In: Singh B, Jain NK, Katare OP, eds. Drug nanocarriers. Series Nanobiomedicine. Houston LLC (USA): Studium Press; 2014:203--55
   Google Scholar
• Hu FQ, Zhang Y, Du YZ, Yuan H. Nimodipine loaded lipid nanospheres prepared by solvent diffusion method in a drug saturated aqueous system. Int J Pharm 2008;348:146–52
   PubMed Web of Science ®Google Scholar
• Kreuter J, Ramge P, Petrov V, et al. Direct evidence that Polysorbate-80-coatedpoly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanism requiring prior binding of drugs to the nanoparticles. Pharm Res 2008; 20:409–16
   Web of Science ®Google Scholar
• Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solutes from liposomes without dilution. J Anal Biochem 1978;90:809–15
   PubMed Web of Science ®Google Scholar
• Grundy JS, Raheem K, Robert TF. Sensitive high-performance liquid chromatographic assay for nifedipine in human plasma utilizing ultraviolet detection. J Chromatogr B: Biomed Sci Appl 1994;654:146–51
   Web of Science ®Google Scholar
• Zendelovska D, Simeska S, Sibinovska O, et al. Development of an HPLC method for the determination of nifedipine in human plasma by solid-phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2006;839:85–8
   PubMed Web of Science ®Google Scholar
• Bishnoi M, Jain A, Hurkat P, Jain SK. Aceclofenac-loaded chondroitin sulphate conjugated SLNs for effective management of osteoarthritis. J Drug Target 2014. [Epub ahead of print]. DOI: 10.3109/1061186X.2014.928714
   Google Scholar
• Fornari FA, Jarvis WD, Grant S, et al. Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Differ 1994;5:723–33
   PubMedGoogle Scholar
• Zhang J, Clark JR, Herman EH, Ferrans VJ. Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187. J Mol Cell Cardiol 1996;28:1931–43
   PubMed Web of Science ®Google Scholar
• Kharya P, Jain A, Gulbake A, et al. Phenylalanine coupled solid lipid nanoparticles for brain tumor targeting. J Nanopart Res 2013;15:1–12
   Web of Science ®Google Scholar
• Kim BD, Na K, Choi HK. Preparation and characterization of solid lipid nanoparticles (SLN) made of cacao butter and curdlan. Eur J Pharm Sci 2005;24:199–205
   PubMed Web of Science ®Google Scholar
• Jain A, Gulbake A, Jain A, et al. Dual drug delivery using “smart” liposomes for triggered release of anticancer agents. J Nanopart Res 2013;15:1–12
   Web of Science ®Google Scholar
• MuÈller RH, Karsten M, Sven G. Solid lipid nanoparticles (SLN) for controlled drug delivery–a review of the state of the art. Eur J Pharm Biopharm 2000;50:161–77
   PubMed Web of Science ®Google Scholar
• Alyautdin R, Khalin I, Nafeeza MI, et al. Nanoscale drug delivery systems and the blood–brain barrier. Intern J Nanomed 2014;9:795–811
   PubMed Web of Science ®Google Scholar
• Sun W, Xie C, Wang H, Hu Y. Specific role of polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomater 2004;25:3065–71
   PubMed Web of Science ®Google Scholar
• Goppert TM, Muller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target 2005;13:179–87
   PubMed Web of Science ®Google Scholar